Diurnal is an innovative pharmaceutical, venture capital-backed,
company that creates high-value hormone therapeutics using
proprietary formulations and novel physiological treatment regimens
of approved drugs.
Diurnal addresses the major unmet clinical and patient needs for
hormone replacement treatments by creating more effective products
for life-long treatment for chronic conditions, including adrenal
insufficiency, rheumatoid arthritis, hypogonadism, and
Diurnal's lead therapy is Chronocort® (circadian
hydrocortisone) for the treatment of Congenital Adrenal Hyperplasia
and Adrenal Insufficiency in adults.